Author:
Zhang Yujuan,Wang Zhigang,Huang Yanqing,Ying Muying,Wang Yifan,Xiong Juan,Liu Qi,Cao Fan,Joshi Rakesh,Liu Yanling,Xu Derong,Zhang Meng,Yuan Keng,Zhou Nanjin,Koropatnick James,Min Weiping
Funder
National Natural Science Foundation of China
Natural Science Foundation of Jiangxi Province
Publisher
Springer Science and Business Media LLC
Reference58 articles.
1. Damaskos, C. et al. Histone deacetylase inhibitors as a novel targeted therapy against non-small cell lung cancer: where are we now and what should we expect? Anticancer Res. 38, 37–43 (2018).
2. Torre, L. A. et al. Global cancer statistics, 2012. Cancer J. Clin. 65, 87–108 (2015).
3. Novello, S. et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27, v1–v27 (2016).
4. Greve, G. et al. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer 15, 947 (2015).
5. Hotta, K. et al. Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation. Oncol. Rep. 17, 313–317 (2007).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献